Exam Details
Subject | clinical research and pharmacy practice | |
Paper | ||
Exam / Course | m.pharm | |
Department | ||
Organization | Gujarat Technological University | |
Position | ||
Exam Date | November, 2017 | |
City, State | gujarat, ahmedabad |
Question Paper
Seat No.: Enrolment No.
GUJARAT TECHNOLOGICAL UNIVERSITY
M. Pharm SEMESTER-III EXAMINATION WINTER 2017
Subject Code: 930103 Date: 10-11-2017
Subject Name: Clinical Research and Pharmacy Practice
Time: 10:30 am to 01:30 pm Total Marks: 80
Instructions:
1. Attempt any five questions.
2. Make suitable assumptions wherever necessary.
3. Figures to the right indicate full marks.
Q.1
Explain the flow of drug development process. Discuss phase I trial in detail.
06
What are the problems in transplantation? How it is managed?
05
Enlist contraindicated drugs during pregnancy and lactation with explanation.
05
Q.2
Explain Drug-Drug interactions of clinical relevance giving suitable examples. What are the methods for minimizing adverse drug interactions?
06
Explain rational drug therapy. Describe the role of pharmacist in overcoming irrational prescribing of drugs.
05
Describe the factors affecting drug response in different racial, ethnic and sex groups.
05
Q.3
Write composition and responsibilities of IRB.
06
Write short note on Investigator Brochure.
05
Discuss various Hematological parameters with their clinical significance.
05
Q.4
Explain the clinical pharmacokinetic parameters and illustrate their significance in patient care.
06
Write short note on Critical Care Therapy.
05
Discuss in brief important aspects of NDA regulations.
05
Q.5
What is inform consent? Write in brief about inform consent process.
06
What is pharmacovigilance? Discuss its status in India. How it can be improved?
05
Explain general principle of clinical toxicology.
05
Q. 6
Describe principles and goals of geriatric therapy.
06
Discuss role and responsibility of Investigator as per ICH GCP guideline.
05
Define ANDA. Discuss AND Application for generic drugs.
05
Q.7
What is TDM? Explain the situations where TDM is useful.
06
Justify clinical investigation of a new drug. Describe phase-I study of clinical trials.
05
Define pharmacoepidemiology. Explain the methods used in epidemiological studies.
05
GUJARAT TECHNOLOGICAL UNIVERSITY
M. Pharm SEMESTER-III EXAMINATION WINTER 2017
Subject Code: 930103 Date: 10-11-2017
Subject Name: Clinical Research and Pharmacy Practice
Time: 10:30 am to 01:30 pm Total Marks: 80
Instructions:
1. Attempt any five questions.
2. Make suitable assumptions wherever necessary.
3. Figures to the right indicate full marks.
Q.1
Explain the flow of drug development process. Discuss phase I trial in detail.
06
What are the problems in transplantation? How it is managed?
05
Enlist contraindicated drugs during pregnancy and lactation with explanation.
05
Q.2
Explain Drug-Drug interactions of clinical relevance giving suitable examples. What are the methods for minimizing adverse drug interactions?
06
Explain rational drug therapy. Describe the role of pharmacist in overcoming irrational prescribing of drugs.
05
Describe the factors affecting drug response in different racial, ethnic and sex groups.
05
Q.3
Write composition and responsibilities of IRB.
06
Write short note on Investigator Brochure.
05
Discuss various Hematological parameters with their clinical significance.
05
Q.4
Explain the clinical pharmacokinetic parameters and illustrate their significance in patient care.
06
Write short note on Critical Care Therapy.
05
Discuss in brief important aspects of NDA regulations.
05
Q.5
What is inform consent? Write in brief about inform consent process.
06
What is pharmacovigilance? Discuss its status in India. How it can be improved?
05
Explain general principle of clinical toxicology.
05
Q. 6
Describe principles and goals of geriatric therapy.
06
Discuss role and responsibility of Investigator as per ICH GCP guideline.
05
Define ANDA. Discuss AND Application for generic drugs.
05
Q.7
What is TDM? Explain the situations where TDM is useful.
06
Justify clinical investigation of a new drug. Describe phase-I study of clinical trials.
05
Define pharmacoepidemiology. Explain the methods used in epidemiological studies.
05
Other Question Papers
Subjects
- advanced medicinal chemistry
- advanced organic chemistry-i
- advanced organic chemistry-ii
- advanced pharmacology ii
- advanced pharmacology-i
- advances in drug delivery system
- advances in pharmacology
- applied pharmacotherapeutics - ii
- applied pharmacotherapeutics-i
- audits and regulatory compliance
- biological evaluations & clinical research
- cellular and molecular pharmacology
- clinical and hospital pharmacy
- clinical pharmacy practice
- clinical research and pharmacy practice
- clinical research and regulatory affairs
- clinical research regulations
- cosmetic and cosmeceuticals
- documentation and regulatory writing
- drug design and discovery
- drug regulation and regulatory authority
- experimental design and patents
- global regulatory requirements
- gmp, glp and validation
- good manufacturing and good laboratory practice
- good manufacturing practice and process validation
- good regulatory practices
- hazards and safety management
- industrial pharmacy practice
- modern analytical techniques
- modern pharmaceutical analysis
- novel drug delivery system part-i
- novel drug delivery system-ii
- pharm. management -ii
- pharmaceutical analysis ii
- pharmaceutical and cosmetic analysis
- pharmaceutical formulation and development
- pharmaceutical formulation development and biopharmceutics
- pharmaceutical manufacturing technology
- pharmaceutical production management & technology
- pharmaceutical regulatory affairs
- pharmacological and toxicological screening methods-i
- pharmacological and toxicological screening methods-ii
- pharmacometrics and methods of biological evaluation of drugs
- pharmacotherapeutics
- principles of biopharmaceutics& pharmacokinetics
- product development and technology transfer
- quality control & quality assurance
- quality control and quality assurance
- quality management system
- regulatory affairs - i
- regulatory affairs and new drug applications
- regulatory aspects of hebbal and biologicals
- research methodology
- validation and product development